These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25287483)

  • 41. [Development status of DAA against hepatitis C].
    Kato N; Nakagawa R; Goto K; Muroyama R; Matsubara Y
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():262-8. PubMed ID: 26845942
    [No Abstract]   [Full Text] [Related]  

  • 42. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice.
    McHutchison JG; Bartenschlager R; Patel K; Pawlotsky JM
    J Hepatol; 2006 Feb; 44(2):411-21. PubMed ID: 16364491
    [No Abstract]   [Full Text] [Related]  

  • 43. Procyanidin B1 purified from Cinnamomi cortex suppresses hepatitis C virus replication.
    Li S; Kodama EN; Inoue Y; Tani H; Matsuura Y; Zhang J; Tanaka T; Hattori T
    Antivir Chem Chemother; 2010 Aug; 20(6):239-48. PubMed ID: 20710064
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bayesian network meta-analysis to evaluate interferon-free treatments in naive patients with genotype 1 hepatitis C virus infection.
    Trippoli S; Fadda V; Maratea D; Messori A
    Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):983-4. PubMed ID: 26114910
    [No Abstract]   [Full Text] [Related]  

  • 45. Miravirsen works against hepatitis C virus.
    BMJ; 2013 Apr; 346():f2069. PubMed ID: 23553883
    [No Abstract]   [Full Text] [Related]  

  • 46. Secreted Interferon-Inducible Factors Restrict Hepatitis B and C Virus Entry In Vitro.
    Xia Y; Cheng X; Blossey CK; Wisskirchen K; Esser K; Protzer U
    J Immunol Res; 2017; 2017():4828936. PubMed ID: 28367455
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel therapies in Hepatitis C virus. Preface.
    Pockros PJ
    Clin Liver Dis; 2009 Aug; 13(3):xiii. PubMed ID: 19628152
    [No Abstract]   [Full Text] [Related]  

  • 48. Interfering with interferon: re-igniting the debate on calcineurin inhibitor choice and antiviral therapy for hepatitis C virus recurrence.
    Watashi K; Metselaar HJ; van der Laan LJ
    Liver Transpl; 2008 Mar; 14(3):265-7. PubMed ID: 18306373
    [No Abstract]   [Full Text] [Related]  

  • 49. A Novel Class of Small Molecule Compounds that Inhibit Hepatitis C Virus Infection by Targeting the Prohibitin-CRaf Pathway.
    Liu S; Wang W; Brown LE; Qiu C; Lajkiewicz N; Zhao T; Zhou J; Porco JA; Wang TT
    EBioMedicine; 2015 Nov; 2(11):1600-6. PubMed ID: 26870784
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.
    Vausselin T; Séron K; Lavie M; Mesalam AA; Lemasson M; Belouzard S; Fénéant L; Danneels A; Rouillé Y; Cocquerel L; Foquet L; Rosenberg AR; Wychowski C; Meuleman P; Melnyk P; Dubuisson J
    J Virol; 2016 Oct; 90(19):8422-34. PubMed ID: 27412600
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Issues in need for a solution among patients with successful eradication of hepatitis C virus].
    Kurosaki M; Izumi N
    Nihon Shokakibyo Gakkai Zasshi; 2016; 113(1):29-35. PubMed ID: 26743551
    [No Abstract]   [Full Text] [Related]  

  • 52. The drugs can work.
    Nat Rev Microbiol; 2012 May; 10(5):307. PubMed ID: 22629548
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment for hepatitis C in patients infected with human immunodeficiency virus.
    Fernández I; Muñoz R; Solís-Herruzo JA
    Rev Esp Enferm Dig; 2003 Apr; 95(4):287-91, 282-6. PubMed ID: 12826005
    [No Abstract]   [Full Text] [Related]  

  • 54. [BMS-790 052 - an oral antiviral hepatitis C antiviral in the pipeline].
    Schmitz J
    Pharm Unserer Zeit; 2011 Jan; 40(1):8-9. PubMed ID: 21194074
    [No Abstract]   [Full Text] [Related]  

  • 55. Hepatitis C virus therapies.
    Smith RE
    Nat Rev Drug Discov; 2006 Sep; 5(9):715-6. PubMed ID: 17001802
    [No Abstract]   [Full Text] [Related]  

  • 56. Locking out hepatitis C.
    Gerold G; Rice CM
    Nat Med; 2011 May; 17(5):542-4. PubMed ID: 21546968
    [No Abstract]   [Full Text] [Related]  

  • 57. [Clinical timing and benefit of antiviral treatment for hepatitis C].
    Chen LC; Xie Q
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):164-169. PubMed ID: 28482401
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In brief: Hepatic injury with hepatitis C drugs.
    Med Lett Drugs Ther; 2015 Nov; 57(1481):156. PubMed ID: 26529136
    [No Abstract]   [Full Text] [Related]  

  • 59. Novel hepatitis C drugs in current trials.
    Kronenberger B; Welsch C; Forestier N; Zeuzem S
    Clin Liver Dis; 2008 Aug; 12(3):529-55, viii. PubMed ID: 18625427
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hepatitis B and C Viruses and Biologics.
    Grewal P; Sanghera R
    Skin Therapy Lett; 2017 Jul; 22(4):7-9. PubMed ID: 28732153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.